Genomics is a fast-growing, rapidly evolving industry and the
ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a prime example of an exchange traded fund that’s nimble enough to capture that evolution.
ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring healthcare, agriculture, and pharmaceuticals in the process.
Next generation sequencing (NGS), including long read DNA, is an example of an evolving frontier ARKG puts investors at the forefront of.
“Now that the clinical community is capitalizing on their speed and scale, ARK believes that the shortcomings of SRS-generated data are becoming more obvious.
The
ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a prime example of an exchange traded fund with lots of levers to pull. Since it’s an actively managed fund, it’s worth examining some of the stocks that could propel ARKG higher this year.
ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process.
In a recent CNBC interview, ARK analyst Simon Barnett highlighted some of the names that could power ARKG to the upside, including Adaptive Biotechnologies.
Cancer Detection Meets Portfolio Perfection: The ARKG ETF
Early cancer detection is an emerging frontier for healthcare companies. The
ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process.
“The Federal Drug Administration (FDA) recently granted Bluestar Genomics, a private company, a Breakthrough Device Designation for its liquid biopsy-based pancreatic cancer screening test,” writes ARK analyst Simon Barnett. “Stanford University researchers focusing on precision epigenomics founded Bluestar Genomics. Unlike those from GRAIL and Exact Sciences (EXAS), Bluestar’s tests focus on a biomarker called 5-hydroxymethylcytosine or 5hmC. 5hmC signals an epigenetic change in the genome that could
The ARKG ETF: Genomics Exposure with a Twist
The
ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is obviously positioned as a genomics fund, but as an actively managed exchange traded fund, it can venture into other growth areas in the healthcare sector.
That includes telemedicine, as highlighted by the fund’s significant exposure to Teledoc (NYSE: TDOC).
ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process.
How ARKG s Genomics Will Personalize Cancer Treatment etftrends.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etftrends.com Daily Mail and Mail on Sunday newspapers.